Repligen | RGEN - 销售成本



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.27B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


销售成本 更改 日
Agilent USD 845M 7M 2026-03
Align Technology USD 298.76M 4.74M 2026-06
Bio Techne USD 103.13M 1.47M 2026-03
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Bruker USD 422.5M 21.1M 2026-06
Charles River Laboratories USD 655.29M 61.22M 2026-06
Danaher USD 2.65B 294M 2026-06
Dentsply International USD 405M 48M 2026-06
General Electric Aerospace USD 8.89B 736M 2026-06
Henry Schein USD 2.43B 129M 2026-06
Illumina USD 389M 19M 2026-06
IQVIA Holdings USD 3.22B 141M 2026-06
Mettler Toledo International USD 396.52M 14.4M 2026-06
Myriad Genetics USD 63M 1.1M 2025-12
OraSure Technologies USD 15.43M 113K 2025-12
Pacific Biosciences Of California USD 28.9M 10M 2025-12
Pfizer USD 4.09B 498M 2026-06
Repligen USD 94.09M 8.12M 2026-06
Revvity USD 312.82M 10.64M 2026-06
Standard Biotools USD 9.84M 2.58M 2026-03
Thermo Fisher Scientific USD 7.54B 577M 2026-06
Waters USD 1.16B 430M 2026-06
West Pharmaceutical Services USD 543.1M 5.4M 2026-06